Full Press Release Details
Early HSR Clearance for Global Strategic Collaboration with
December 16, 2014 Geron Corporation (Nasdaq: GERN) announced today
that the Federal Trade Commission has granted early termination of the waiting
period under the Hart-Scott-Rodino Antitrust Improvement Acts of 1976 (HSR Act)
in connection with the exclusive worldwide license and collaboration agreement
executed by the company on November 13, 2014 with Janssen Biotech, Inc.
(Janssen) to develop and commercialize, imetelstat, Geron's telomerase inhibitor
With the early termination of
the applicable waiting period under the HSR Act, the collaboration agreement
with Janssen is effective as of December 15, 2014 and the $35 million initial
payment under the collaboration agreement is due to the company.
Additional details regarding
the collaboration can be found in Geron's Form 8-K filed with the Securities and
Exchange Commission on November 13, 2014.
Geron is a clinical stage
biopharmaceutical company developing a first-in-class telomerase inhibitor,
imetelstat, in hematologic myeloid malignancies. For more information about
Geron, visit www.geron.com.